odmj
OncoDaily Medical Journal
ODMJ
3067-6444
OncoDaily Medical Journal
US
7512
10.69690/odmj-012-0426-7512
Commentaries
Frailty, infections, and bispecific antibodies in multiple myeloma: redefining supportive care in the era of T-cell redirection
https://orcid.org/0000-0001-8373-0532
Spataro
Federico
Department of Precision and Regenerative Medicine and Ionian Area – DiMePRe-J, Section of Pharmacology, University of Bari Aldo Moro, 70124 Bari, Italy
Department of Precision and Regenerative Medicine and Ionian Area – DiMePRe-J, Guido Baccelli Unit of Internal Medicine, School of Medicine, University of Bari Aldo Moro, 70124 Bari, Italy
Desantis
Vanessa
Department of Precision and Regenerative Medicine and Ionian Area – DiMePRe-J, Section of Pharmacology, University of Bari Aldo Moro, 70124 Bari, Italy
Dicuonzo
Giuseppe
Department of Precision and Regenerative Medicine and Ionian Area – DiMePRe-J, Guido Baccelli Unit of Internal Medicine, School of Medicine, University of Bari Aldo Moro, 70124 Bari, Italy
https://orcid.org/0000-0002-4567-8216
Vacca
Angelo
Department of Precision and Regenerative Medicine and Ionian Area – DiMePRe-J, Guido Baccelli Unit of Internal Medicine, School of Medicine, University of Bari Aldo Moro, 70124 Bari, Italy
https://orcid.org/0000-0002-1515-0090
Ria
Roberto
Department of Precision and Regenerative Medicine and Ionian Area – DiMePRe-J, Guido Baccelli Unit of Internal Medicine, School of Medicine, University of Bari Aldo Moro, 70124 Bari, Italy
https://orcid.org/0000-0002-9104-5436
Cerchione
Claudio
Hematology Unit, Istituto Romagnolo per lo Studio dei Tumori “Dino Amadori”-IRST IRCCS, Via Piero Maroncelli 40, 47014 Meldola, FC, Italy
https://orcid.org/0000-0002-2293-9698
Solimando
Antonio Giovanni
Department of Precision and Regenerative Medicine and Ionian Area – DiMePRe-J, Guido Baccelli Unit of Internal Medicine, School of Medicine, University of Bari Aldo Moro, 70124 Bari, Italy
antonio.solimando@uniba.it
24
04
2026
odmj-012-0426-7512
Copyright (c) 2026 OncoDaily Medical Journal
2026
OncoDaily Medical Journal
Bispecific Antibodies
IGRT
Immunoglobulin Replacement Treatment
Infections
Multiple Myeloma
Special Series
production-ready-file-url
[
Kyle RA, Rajkumar SV. Multiple myeloma. Blood. 2008 Mar 15;111:2962-72.
]
[
Allegra A, Tonacci A, Musolino C, et al. Secondary immunodeficiency in hematological malignancies: focus on multiple myeloma and chronic lymphocytic leukemia. Front Immunol. 2021 Oct 25;12:738915.
]
[
Jolles S, Giralt S, Kerre T, et al. Agents contributing to secondary immunodeficiency development in patients with multiple myeloma, chronic lymphocytic leukemia and non-Hodgkin lymphoma: a systematic literature review. Front Oncol. 2023 Feb 7;13:1098326.
]
[
Rodriguez-Otero P, Usmani S, Cohen AD, et al. International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma. Lancet Oncol. 2024 May;25:e205-e216.
]
[
Ludwig H, Terpos E, van de Donk N, et al. Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network. Lancet Oncol. 2023 Jun;24:e255-e269.
]
[
Palumbo A, Bringhen S, Mateos MV, et al. Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report. Blood. 2015 Mar 26;125:2068-74.
]
[
Zhang Y, Liang X, Xu W, et al. Individualized dynamic frailty-tailored therapy (DynaFiT) in elderly patients with newly diagnosed multiple myeloma: a prospective study. J Hematol Oncol. 2024 Jun 24;17:48.
]
[
Spataro F, Armentaro G, Di Gioia G, et al. Impact of frailty on infection risk in non-transplant eligible multiple myeloma patients: a systematic review and meta-analysis. Leukemia. 2026 Feb 17.
]
[
Mateos MV, Dimopoulos MA, Cavo M, et al. Daratumumab plus bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of ALCYONE. Clin Lymphoma Myeloma Leuk. 2021 Nov;21:785-798.
]
[
Facon T, Cook G, Usmani SZ, et al. Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIA. Leukemia. 2022 Apr;36:1066-1077.
]
[
Li H, Manwani B, Leng SX. Frailty, inflammation, and immunity. Aging Dis. 2011 Dec;2:466-73.
]
[
Vacca A, Melaccio A, Sportelli A, et al. Subcutaneous immunoglobulins in patients with multiple myeloma and secondary hypogammaglobulinemia: a randomized trial. Clin Immunol. 2018 Jun;191:110-115.
]
[
Jolles S, Michallet M, Agostini C, et al. Treating secondary antibody deficiency in patients with haematological malignancy: European expert consensus. Eur J Haematol. 2021 Apr;106:439-449.
]
[
Raje N, Anderson K, Einsele H, et al. Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel. Blood Cancer J. 2023 Aug 1;13:116.
]
[
Cheruvalath H, Clennon A, Shresth A, et al. Effects of intravenous immunoglobulin supplementation (IVIG) on infections in recipients of teclistamab therapy for multiple myeloma (MM): a multi-institutional study. Blood. 2024;144 Suppl 1:256.
]
[
Frerichs KA, Verkleij CPM, Mateos MV, et al. Teclistamab impairs humoral immunity in patients with heavily pretreated myeloma: importance of immunoglobulin supplementation. Blood Adv. 2024 Jan 9;8:194-206.
]
[
Lancman G, Parsa K, Kotlarz K, et al. IVIg use associated with ten-fold reduction of serious infections in multiple myeloma patients treated with anti-BCMA bispecific antibodies. Blood Cancer Discov. 2023 Nov 1;4:440-451.
]
[
Mohan M, Monge J, Shah N, et al. Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study. Blood Cancer J. 2024 Mar 5;14:35.
]
[
Piron B, Rodrigo L, Tessoulin B, et al. Preemptive immunoglobulin prophylaxis reduces infections in patients treated with anti-BCMA bispecific antibodies. Clin Lymphoma Myeloma Leuk. 2025 Oct 31:S2152-2650(25)04264-8.
]
[
Sheu M, Molina Garcia S, Patel M, et al. Infection prophylaxis with intravenous immunoglobulin in multiple myeloma patients treated with teclistamab. Oncology. 2025 Oct 23:1-5.
]